Melanoma vaccines

References

• Wiemann B, Starnes CO. Coley’s toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol. Ther.64(3), 529–564 (1994).
   PubMed Web of Science ®Google Scholar
• Kessler E, Schwartz P, Antebi E. Spontaneous regression of primary malignant melanoma with metastases. Plast. Reconstr. Surg.74(3), 427–429 (1984).
   PubMed Web of Science ®Google Scholar
• Satzger I, Schenck F, Kapp A, Gutzmer R. Spontaneous regression of melanoma with distant metastases – report of a patient with brain metastases. Eur. J. Dermatol.16(4), 454–455 (2006).
   Google Scholar
• Wankowicz-Kalinska A, Le Poole C, van den Wijngaard R, Storkus WJ, Das PK. Melanocyte-specific immune response in melanoma and vitiligo: two faces of the same coin? Pigment Cell Res.16(3), 254–260 (2003).
   PubMedGoogle Scholar
• Kim R. Cancer immunoediting: from immune surveillance to immune escape. In: Cancer Immunotherapy: Immune Suppression and Tumor Growth. Prendergast G, Jaffee E (Eds). Elsevier, NY, USA 9–25 (2007).
   Google Scholar
• Wang RF, Miyahara Y, Wang HY. Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene27(2), 181–189 (2008).
   PubMed Web of Science ®Google Scholar
• Wang RF, Rosenberg SA. Human tumor antigens for cancer vaccine development. Immunol. Rev.170, 85–100 (1999).
   PubMed Web of Science ®Google Scholar
• Bodurtha AJ, Chee DO, Laucius JF, Mastrangelo MJ, Prehn RT. Clinical and immunological significance of human melanoma cytotoxic antibody. Cancer Res.35(1), 189–193 (1975).
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Ibrahim JG, Sosman JA et al. High-dose interferon α-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB–III melanoma: results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol.19(9), 2370–2380 (2001).
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Mascari RA, Edington HD et al. Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma. Cancer88(12), 2693–2702 (2000).
   Google Scholar
• Saleh MN, Khazaeli MB, Wheeler RH et al. Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res.52(16), 4342–4347 (1992).
   PubMed Web of Science ®Google Scholar
• Hanai N, Nakamura K, Shitara K. Recombinant antibodies against ganglioside expressed on tumor cells. Cancer Chemother. Pharmacol.46(Suppl.) S13–S17 (2000).
   PubMed Web of Science ®Google Scholar
• King DM, Albertini MR, Schalch H et al. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J. Clin. Oncol.22(22), 4463–4473 (2004).
   PubMed Web of Science ®Google Scholar
• Lee FT, Rigopoulos A, Hall C et al. Specific localization, g camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts. Cancer Res.61(11), 4474–4482 (2001).
   PubMed Web of Science ®Google Scholar
• Li B, Wang H, Zhang D et al. Construction and characterization of a high-affinity humanized SM5-1 monoclonal antibody. Biochem. Biophys. Res. Commun.357(4), 951–956 (2007).
   Google Scholar
• Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu. Rev. Immunol.24, 175–208 (2006).
   PubMed Web of Science ®Google Scholar
• Vujanovic L, Butterfield LH. Melanoma cancer vaccines and anti-tumor T cell responses. J. Cell. Biochem.102(2), 301–310 (2007).
   PubMed Web of Science ®Google Scholar
• Melief CJ. Mini-review: regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming? Eur. J. Immunol.33(10), 2645–2654 (2003).
   PubMed Web of Science ®Google Scholar
• Schijns VE. Mechanisms of vaccine adjuvant activity: initiation and regulation of immune responses by vaccine adjuvants. Vaccine21(9–10), 829–831 (2003).
   PubMed Web of Science ®Google Scholar
• Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol.13, 399–415 (1995).
   PubMed Web of Science ®Google Scholar
• Salgaller ML, Lodge PA. Use of cellular and cytokine adjuvants in the immunotherapy of cancer. J. Surg. Oncol.68(2), 122–138 (1998).
   PubMed Web of Science ®Google Scholar
• Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene27(2), 161–167 (2008).
   PubMed Web of Science ®Google Scholar
• von Meyenn F, Schaefer M, Weighardt H et al. Toll-like receptor 9 contributes to recognition of Mycobacterium bovis bacillus Calmette–Guerin by Flt3-ligand generated dendritic cells. Immunobiology211(6–8), 557–565 (2006).
   PubMedGoogle Scholar
• Vulink A, Radford KJ, Melief C, Hart DN. Dendritic cells in cancer immunotherapy. Adv. Cancer Res.99, 363–407 (2008).
   PubMedGoogle Scholar
• Spitler L, Grossbard M, Ernstoff M et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte–macrophage colony-stimulating factor. J. Clin. Oncol.18, 1614–1621 (2000).
   PubMed Web of Science ®Google Scholar
• Leong SP, Enders-Zohr P, Zhou YM et al. Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. J. Immunother.22(2), 166–174 (1999).
   PubMed Web of Science ®Google Scholar
• Bendandi M, Gocke CD, Kobrin CB et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma. Nat. Med.5(10), 1171–1177 (1999).
   PubMed Web of Science ®Google Scholar
• Pasquini S, Peralta S, Missiaglia E, Carta L, Lemoine NR. Prime–boost vaccines encoding an intracellular idiotype/GM-CSF fusion protein induce protective cell-mediated immunity in murine pre-B cell leukemia. Gene Ther.9(8), 503–510 (2002).
   PubMed Web of Science ®Google Scholar
• Tripathi PK, Qin H, Bhattacharya-Chatterjee M, Ceriani RL, Foon KA, Chatterjee SK. Construction and characterization of a chimeric fusion protein consisting of an anti-idiotype antibody mimicking a breast cancer-associated antigen and the cytokine GM-CSF. Hybridoma18(2), 193–202 (1999).
   Google Scholar
• Sun X, Hodge LM, Jones HP, Tabor L, Simecka JW. Co-expression of granulocyte–macrophage colony-stimulating factor with antigen enhances humoral and tumor immunity after DNA vaccination. Vaccine20(9–10), 1466–1474 (2002).
   PubMed Web of Science ®Google Scholar
• Rasko J, Gough N. Granulocyte–macrophage colony stimulating factor. In: The Cytokine Handbook. Thomson A (Ed.). Academic Press, San Diego, CA, USA 343–370 (1994).
   Google Scholar
• Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte–macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA90(8), 3539–3543 (1993).
   PubMed Web of Science ®Google Scholar
• Berinstein NL. Enhancing cancer vaccines with immunomodulators. Vaccine25(Suppl. 2), B72–B88 (2007).
   PubMed Web of Science ®Google Scholar
• Celis E. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction. Cancer110(1), 203–214 (2007).
   PubMed Web of Science ®Google Scholar
• Luiten RM, Kueter EW, Mooi W et al. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J. Clin. Oncol.23(35), 8978–8991 (2005).
   PubMed Web of Science ®Google Scholar
• Markovic SN, Suman VJ, Ingle JN et al. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization. Am. J. Clin. Oncol.29(4), 352–360 (2006).
   PubMed Web of Science ®Google Scholar
• Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev.13(2), 155–168 (2002).
   PubMed Web of Science ®Google Scholar
• Del Vecchio M, Bajetta E, Canova S et al. Interleukin-12: biological properties and clinical application. Clin. Cancer Res.13(16), 4677–4685 (2007).
   PubMed Web of Science ®Google Scholar
• Lens M. The role of vaccine therapy in the treatment of melanoma. Expert Opin. Biol. Ther.8(3), 315–323 (2008).
   PubMed Web of Science ®Google Scholar
• Terando AM, Faries MB, Morton DL. Vaccine therapy for melanoma: current status and future directions. Vaccine25(Suppl. 2), B4–B16 (2007).
   PubMed Web of Science ®Google Scholar
• Ralph SJ. An update on malignant melanoma vaccine research: insights into mechanisms for improving the design and potency of melanoma therapeutic vaccines. Am. J. Clin. Dermatol.8(3), 123–141 (2007).
   PubMed Web of Science ®Google Scholar
• Haigh PI, Difronzo LA, Gammon G, Morton DL. Vaccine therapy for patients with melanoma. Oncology (Williston Park)13(11), 1561–1574 (1999).
   PubMed Web of Science ®Google Scholar
• Berd D. M-Vax: an autologous, hapten-modified vaccine for human cancer. Expert Rev. Vaccines3(5), 521–527 (2004).
   PubMedGoogle Scholar
• Testori A, Richards J, Whitman E et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician’s choice of treatment for stage IV melanoma: the C-100-21 study group. J. Clin. Oncol.26(6), 955–962 (2008).
   PubMed Web of Science ®Google Scholar
• Morton DL, Thompson JF, Kashani-Sabet M, Kelley M, Gammon G. An international, randomized, double-blind, Phase 3 study of the specific active immunotherapy agent, onamelatucel-L (CanvaxinTM), compared with placebo as a post-surgical adjuvant in AJCC stage IV melanoma. Ann. Surg. Oncol.13(Suppl. 2), 5 (2006).
   Google Scholar
• Sosman JA, Unger JM, Liu PY et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J. Clin. Oncol.20(8), 2067–2075 (2002).
   PubMed Web of Science ®Google Scholar
• Mitchell MS, Abrams J, Thompson JA et al. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon α-2b compared with high-dose interferon α-2b for resected stage III cutaneous melanoma. J. Clin. Oncol.25(15), 2078–2085 (2007).
   PubMed Web of Science ®Google Scholar
• Tan JK, Ho VC. Pooled analysis of the efficacy of bacille Calmette–Guerin (BCG) immunotherapy in malignant melanoma. J. Dermatol. Surg. Oncol.19(11), 985–990 (1993).
   PubMedGoogle Scholar
• Agarwala SS, Neuberg D, Park Y, Kirkwood JM. Mature results of a Phase III randomized trial of bacillus Calmette–Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on cancer stage I–III melanoma (E1673): a trial of the Eastern oncology group. Cancer100(8), 1692–1698 (2004).
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr, Petroni GR, Chianese-Bullock KA et al. Immunologic and clinical outcomes of a randomized Phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin. Cancer Res.13(21), 6386–6395 (2007).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med.4(3), 321–327 (1998).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med.10(9), 909–915 (2004).
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Ugurel S, Schuler-Thurner B et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DCs) in first-line treatment of patients with metastatic melanoma: a randomized Phase III trial of the DC study group of the DeCOG. Ann. Oncol.17(4), 563–570 (2006).
   PubMed Web of Science ®Google Scholar
• van Baren N, Bonnet MC, Dreno B et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J. Clin. Oncol.23(35), 9008–9021 (2005).
   PubMed Web of Science ®Google Scholar
• Connerotte T, Van Pel A, Godelaine D et al. Functions of anti-MAGE T-cells induced in melanoma patients under different vaccination modalities. Cancer Res.68(10), 3931–3940 (2008).
   PubMed Web of Science ®Google Scholar
• Livingston PO, Wong GY, Adluri S et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol.12(5), 1036–1044 (1994).
   PubMed Web of Science ®Google Scholar
• Aw D, Silva AB, Palmer DB. Immunosenescence: emerging challenges for an ageing population. Immunology120(4), 435–446 (2007).
   PubMed Web of Science ®Google Scholar
• Stevenson F, Di Genova G, Cottensmeier C, Savelyeva N. Cancer vaccines. In: Cancer Immunotherapy: Immune suppression and Tumor Growth. Prendergast G, Jaffee E (Eds). Elsevier, Boston, MA, USA 183–204 (2007).
   Google Scholar
• Radoja S, Frey AB. Cancer-induced defective cytotoxic T lymphocyte effector function: another mechanism how antigenic tumors escape immune-mediated killing. Mol. Med.6(6), 465–479 (2000).
   PubMed Web of Science ®Google Scholar
• Baniyash M. Chronic inflammation, immunosuppression and cancer: new insights and outlook. Semin. Cancer Biol.16(1), 80–88 (2006).
   PubMed Web of Science ®Google Scholar
• Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer5(4), 263–274 (2005).
   PubMed Web of Science ®Google Scholar
• Gorelik L, Constant S, Flavell RA. Mechanism of transforming growth factor β-induced inhibition of T helper type 1 differentiation. J. Exp. Med.195(11), 1499–1505 (2002).
   PubMed Web of Science ®Google Scholar
• Mangan PR, Harrington LE, O’Quinn DB et al. Transforming growth factor-β induces development of the T(H)17 lineage. Nature441(7090), 231–234 (2006).
   PubMed Web of Science ®Google Scholar
• Marie JC, Letterio JJ, Gavin M, Rudensky AY. TGF-β1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J. Exp. Med.201(7), 1061–1067 (2005).
   PubMed Web of Science ®Google Scholar
• Allavena P, Piemonti L, Longoni D et al. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur. J. Immunol.28(1), 359–369 (1998).
   PubMed Web of Science ®Google Scholar
• Fiorentino DF, Zlotnik A, Vieira P et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol.146(10), 3444–3451 (1991).
   PubMed Web of Science ®Google Scholar
• Gabrilovich D, Ishida T, Oyama T et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood92(11), 4150–4166 (1998).
   PubMed Web of Science ®Google Scholar
• Young MR, Wright MA, Pandit R. Myeloid differentiation treatment to diminish the presence of immune-suppressive CD34+ cells within human head and neck squamous cell carcinomas. J. Immunol.159(2), 990–996 (1997).
   PubMed Web of Science ®Google Scholar
• Wagner SN, Schultewolter T, Wagner C et al. Immune response against human primary malignant melanoma: a distinct cytokine mRNA profile associated with spontaneous regression. Lab. Invest.78(5), 541–550 (1998).
   PubMed Web of Science ®Google Scholar
• Morton DL. In: Society of Surgical Oncology (2006).
   Google Scholar
• Gonzalez R, Hutchins L, Nemunaitis J, Atkins M, Schwarzenberger PO. Phase 2 trial of allovectin-7 in advanced metastatic melanoma. Melanoma Res.16(6), 521–526 (2006).
   PubMed Web of Science ®Google Scholar
• Soiffer R, Hodi FS, Haluska F et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte–macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J. Clin. Oncol.21(17), 3343–3350 (2003).
   PubMed Web of Science ®Google Scholar
• Hersey P, Coates AS, McCarthy WH et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J. Clin. Oncol.20(20), 4181–4190 (2002).
   PubMed Web of Science ®Google Scholar
• Sondak VK, Liu PY, Tuthill RJ et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J. Clin. Oncol.20(8), 2058–2066 (2002).
   PubMed Web of Science ®Google Scholar
• Mitchell MS, Harel W, Kan-Mitchell J et al. Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action. Ann. NY Acad. Sci.690, 153–166 (1993).
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr, Petroni GR, Yamshchikov GV et al. Clinical and immunologic results of a randomized Phase II trial of vaccination using four melanoma peptides either administered in granulocyte–macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J. Clin. Oncol.21(21), 4016–4026 (2003).
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr, Petroni GR, Yamshchikov GV et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J. Clin. Oncol.22(22), 4474–4485 (2004).
   Google Scholar
• Testori A, Richards J, Whitman E et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician’s choice of treatment for stage IV melanoma: the C-100-21 study group. J. Clin. Oncol.26(6), 955–962 (2008).
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Yuan J, Houghton AN et al. Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Mol. Ther.15(11), 2044–2050 (2007).
   PubMed Web of Science ®Google Scholar
• Hamid O, Solomon JC, Scotland R et al. Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Clin. Cancer Res.13(1), 215–222 (2007).
   PubMed Web of Science ®Google Scholar
• Lindsey KR, Gritz L, Sherry R et al. Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma. Clin. Cancer Res.12(8), 2526–2537 (2006).
   PubMed Web of Science ®Google Scholar
• Smith CL, Mirza F, Pasquetto V et al. Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara. J. Immunol.175(12), 8431–8437 (2005).
   PubMed Web of Science ®Google Scholar
• Khong HT, Yang JC, Topalian SL et al. Immunization of HLA-A*0201 and/or HLA-DPβ1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J. Immunother.27(6), 472–477 (2004).
   PubMed Web of Science ®Google Scholar
• Chapman PB, Wu D, Ragupathi G et al. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Clin. Cancer Res.10(14), 4717–4723 (2004).
   PubMed Web of Science ®Google Scholar
• Chapman PB, Williams L, Salibi N, Hwu WJ, Krown SE, Livingston PO. A Phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside. Vaccine22(21–22), 2904–2909 (2004).
   PubMedGoogle Scholar
• Mitchell MS, Kan-Mitchell J, Morrow PR, Darrah D, Jones VE, Mescher MF. Phase I trial of large multivalent immunogen derived from melanoma lysates in patients with disseminated melanoma. Clin. Cancer Res.10(1 Pt 1), 76–83 (2004).
   PubMed Web of Science ®Google Scholar
• Bedrosian I, Mick R, Xu S et al. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J. Clin. Oncol.21(20), 3826–3835 (2003).
   PubMed Web of Science ®Google Scholar
• Nicholson S, Guile K, John J et al. A randomized Phase II trial of SRL172 (Mycobacterium vaccae) ± low-dose interleukin-2 in the treatment of metastatic malignant melanoma. Melanoma Res13(4), 389–393 (2003).
   PubMed Web of Science ®Google Scholar
• Dillman RO, Wiemann M, Nayak SK, DeLeon C, Hood K, DePriest C. Interferon-γ or granulocyte–macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized Phase 2 trial of the cancer biotherapy research group. J. Immunother.26(4), 367–373 (2003).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Sherry RM et al. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum. Gene Ther.14(8), 709–714 (2003).
   PubMed Web of Science ®Google Scholar
• Smith JW 2nd, Walker EB, Fox BA et al. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J. Clin. Oncol.21(8), 1562–1573 (2003).
   PubMed Web of Science ®Google Scholar
• Bettinotti MP, Panelli MC, Ruppe E et al. Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12:170–178. Int. J. Cancer105(2), 210–216 (2003).
   PubMed Web of Science ®Google Scholar